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The study from Laterre and colleagues \[[@B1]\], published in this issue of *Critical Care*, offers suggestions for the role of clinical evaluation committees (CECs) in future sepsis trials. From 1990 to 2000, randomized controlled trials (RCTs) have evaluated a variety of potential therapeutic interventions for severe sepsis. Despite some encouraging results in phase II trials, all RCTs have failed to show survival benefit based upon intention-to-treat analyses \[[@B2]\]. The reasons for these disappointing results might not only reflect the possible lack of efficacy of each new therapy, but may also be related to RCT-related factors that inevitably occur within a heterogeneous septic patient population. Other variables that might occur include variability of medical management strategies and the frequency of protocol violations. Phase II trials use a small number of highly motivated and experienced centers that are less susceptible to confounding events brought about by variations in clinical practices than international RCTs.

A patient population free from confounding events and studied in full compliance with the protocol, including strict adherence to entry criteria, would seem to provide the most suitable platform upon which to judge the therapeutic effect of a new intervention for sepsis. To solve this issue, CECs have been introduced into RCTs in sepsis \[[@B3]-[@B7]\] to ensure uniform data for analysis and to identify such \'optimal cohorts\' for which the therapy was initially designed to treat. As an example, Sprung and colleagues \[[@B8]\] showed that the reduction of mortality was higher in the pre-specified valid cohort than in the overall intent-to-treat study population (26.5 versus 14.5%) when using anti-tumor necrosis factor antibodies for sepsis.

More recently, some RCTs have reported positive results in sepsis \[[@B9],[@B10]\], although these results remain the subject of much debate \[[@B11]\]. Consequently, the role of CECs has shifted to become a more integral part of the detailed analysis of drug safety and efficacy in large international integrated databases of several trials \[[@B12]\], and to identify subgroups of patients in which the therapy might be less \[[@B13]\] or more \[[@B14]\] effective and/or safe.

As an example, the retrospective review of patient subgroups reported by Laterre and colleagues \[[@B1]\] is of great interest. They focus on patients comprising a well defined population at high risk of death from severe community-acquired pneumonia (sCAP) within a large, failed RCT on recombinant tissue factor pathway inhibitor (rTFPI) in severe sepsis. The heterogeneity related to sources of infection, microorganisms, surgical procedures and risk of bleeding is considerably reduced in sCAP when compared to the broad, non-selected, severe sepsis population.

However, as the authors stress, results from small groups of retrospectively selected patients should be interpreted with great caution due to a combination of reduced statistical power, increased variance, multiplicity, and the play of chance; therefore, these results should be viewed only as exploratory and a hypothesis-generating activity. For instance, the significant reduction of mortality with rTFPI observed in the subgroup of sCAP without heparin seems more related to the unexpected high mortality of the placebo group (51.9%) than to a low mortality in the treated group (29.3%). This finding is in agreement with the higher mortality observed in patients on usual-care heparin at baseline who were randomized to placebo than those randomized to heparin in the XPRESS trial assessing the effect of prophylactic heparin in patients with severe sepsis treated with activated protein C \[[@B15]\].

This question of potential benefit of rTFPI in patients with sCAP will be definitively answered by the results of the recently completed phase III CAPTIVATE trial.
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